Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a entry. The Danish drugmaker last month revealed disappointing ...

All things considered, it’s at least as likely to make health outcomes worse as it is to make most people healthier.